DDInter923 DDInter1860
Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases. Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF-α, infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α. Infliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. It is indicated for the treatment
Withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances.
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clobazam
Clobazam {u} (Compound) resembles {v} (Compound) Triazolam
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clobazam
Clobazam {u} (Compound) resembles {v} (Compound) Camazepam
Camazepam {u} (Compound) resembles {v} (Compound) Triazolam
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Theophylline
Theophylline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Halazepam
Halazepam {u} (Compound) resembles {v} (Compound) Triazolam
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clonazepam
Clonazepam {u} (Compound) resembles {v} (Compound) Flunitrazepam
Flunitrazepam {u} (Compound) resembles {v} (Compound) Triazolam
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Thalidomide
Thalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Halazepam
Halazepam {u} (Compound) resembles {v} (Compound) Triazolam
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Thalidomide
Thalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Quazepam
Quazepam {u} (Compound) resembles {v} (Compound) Triazolam
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Theophylline
Theophylline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lorazepam
Lorazepam {u} (Compound) resembles {v} (Compound) Triazolam
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lidocaine
Lidocaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Halazepam
Halazepam {u} (Compound) resembles {v} (Compound) Triazolam
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Aldesleukin
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Halazepam
Halazepam {u} (Compound) resembles {v} (Compound) Triazolam
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Quazepam
Quazepam {u} (Compound) resembles {v} (Compound) Triazolam
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Triazolam (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Camazepam (Compound) and Camazepam (Compound) resembles Triazolam (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Halazepam and Halazepam (Compound) resembles Triazolam (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Clonazepam and Clonazepam (Compound) resembles Flunitrazepam (Compound) and Flunitrazepam (Compound) resembles Triazolam (Compound)
Infliximab may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Halazepam and Halazepam (Compound) resembles Triazolam (Compound)
Infliximab may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Quazepam and Quazepam (Compound) resembles Triazolam (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Lorazepam and Lorazepam (Compound) resembles Triazolam (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Halazepam and Halazepam (Compound) resembles Triazolam (Compound)
Infliximab may lead to a major life threatening interaction when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Halazepam and Halazepam (Compound) resembles Triazolam (Compound)
Infliximab may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Quazepam and Quazepam (Compound) resembles Triazolam (Compound)